Gesynta Pharma's targeted approach to the enzyme mPGES-1 provides more precise treatments for inflammation and pain.
Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain. We are currently developing two drug candidates. Vipoglanstat is in clinical phase 2. A clinical trial in patients with endometriosis was initiated in 2025. Our second drug candidate GS-073 is ready to enter clinical phase 1 for the treatment of chronic inflammatory pain. Read more about our drug development projects.
Development pipeline
Gesynta Pharma develops pharmaceutical treatments of inflammation – a key underlying driver in a spectrum of diseases. The most advanced drug candidate, vipoglanstat, is currently in development as a non-hormonal, non-opioid, disease-modifying treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Vipoglanstat selectively inhibits mPGES-1, an enzyme that promotes production of the proinflammatory mediator prostaglandin E2 (PGE2). In phase 1 and 2 clinical trials, vipoglanstat has demonstrated a favorable safety profile and potent inhibition of mPGES-1. A preclinical proof-of-concept study in an advanced disease model of endometriosis showed that vipoglanstat markedly reduced both pain and endometriotic lesion load. Based on these robust data, Gesynta Pharma has initiated a phase 2 clinical trial of vipoglanstat in patients with endometriosis.
Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, targets the same enzyme as vipoglanstat. GS-073 is ready to enter clinical phase 1 for the treatment of chronic inflammatory pain.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase 2 for endometriosis, while GS-073 is ready to enter clinical phase 1 for chronic inflammatory pain.